Type III group B Streptococcus (GBS) has been a leading cause of neonatal sepsis and meningitis for nearly three decades. Despite advances in neonatal care, the mortality associated with this infection remains as high as 10%. 1 Neutrophil (polymorphonuclear leukocyte (PMN))-mediated killing is essential to host defense against these organisms.
1 Type III GBS, when opsonized with complement and specific antibody (Ab), is killed efficiently by PMNs. However, previous studies suggest that these components of host defense are deficient in the neonate. 2, 3 Furthermore, there are qualitative and quantitative deficiencies in PMN function in neonates. 4 -6 Cytokines, such as tumor necrosis factor-␣ (TNF-␣), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF), augment the bactericidal activity of PMNs from adults against Staphylococcus aureus, nontypable Hemophilus influenzae, Legionella pneumophila, and Candida albicans. [7] [8] [9] [10] [11] Several investigators have proposed that a deficiency in the production of or response to these cytokines may contribute to increased susceptibility to infection in neonates. 4, [12] [13] [14] TNF-␣ is an important mediator in the response of the host to infection and stimulates PMNs by inducing alterations in cell migration, adhesion, oxygen radical production, and degranulation. 15 TNF-␣ as a major monocyte product also increases complement receptor 1 (CR1) and CR3 expression on mature blood PMNs, thereby increasing margination and phagocytic activity. 16 Elevated levels of TNF-␣ have been noted in human neonates with GBS sepsis and in experimental infection; 17, 18 however, the effect of TNF-␣ on PMNmediated killing of III GBS has not been investigated.
G-CSF and GM-CSF are produced by activated T lymphocytes and macrophages. These growth factors mediate the proliferation and differentiation of hematopoietic stem cells and prime adult PMNs (A-PMNs) and neonatal PMNs (N-PMNs) for enhanced oxidative metabolism and chemotaxis. 19 In experimental models of GBS sepsis, administration of GM-CSF or G-CSF improved survival and enhanced bacterial clearance. 20, 21 The proposed mechanisms for this effect are improved granulopoiesis and increased PMN bactericidal activity. These growth factors also increase the surface expression of PMN Original Article
receptors (CR1, CR3, and FcRIII), which are important in PMNmediated phagocytosis of opsonized III GBS. [22] [23] [24] [25] [26] Fleischmann et al. 10 and Cairo et al. 19 demonstrated that GM-CSF enhances A-PMN and N-PMN-mediated phagocytosis of S. aureus in vitro. Similarly, Bober et al. 11 reported that G-CSF increased the phagocytosis and killing of S. aureus by A-PMN.
The present study investigated the hypothesis that TNF-␣, G-CSF, and GM-CSF each would augment PMN-mediated opsonophagocytosis of III GBS. Our results show that TNF-␣ and GM-CSF increase the phagocytosis and intracellular killing of III GBS by PMNs. Given that GM-CSF enhanced the opsonophagocytosis mediated both by A-PMNs and N-PMNs, possible mechanisms for this effect also were studied.
MATERIALS AND METHODS Bacteria
A type III strain of GBS, COH1 (a gift of Dr. Craig Rubens, University of Washington, Seattle, WA), originally isolated from the blood of a neonate, was used in all experiments. The bacteria were grown to mid log phase in Todd-Hewitt broth (Difco Laboratories, Detroit, MI), washed, and resuspended to a concentration of 4 ϫ 10 6 colony-forming units (CFU)/ml in minimum essential medium (BioWhittaker, Walkersville, MD).
PMNs N-PMNs were isolated from cord blood specimens obtained from the placentas of healthy, term infants delivered by elective cesarean section performed with epidural anesthesia. A-PMNs were obtained by venipuncture of healthy adult volunteers. Whole blood was anti-coagulated, and PMNs were purified by methods described previously. 27 The purity and viability of PMNs were Ͼ95% as determined by Wright's staining and trypan blue exclusion, respectively.
Cytokines
Human recombinant TNF-␣, G-CSF, and GM-CSF were purchased from R&D Systems (Minneapolis, MN). The preparations were Ͼ97% pure and contained Ͻ0.1 ng of endotoxin per 1 g of the cytokine as determined by Limulus amoebocyte lysate assay.
Measurement of Cytokines in Serum
Baseline endogenous serum concentrations of TNF-␣, G-CSF, and GM-CSF in five cord blood specimens and five adult blood specimens were determined with Predicta TNF-␣ and GM-CSF enzyme-linked immunosorbent assay kits (Genzyme, Cambridge, MA) and with a Quantikine human G-CSF enzyme-linked immunosorbent assay kit (R&D Systems). The lower limits of detection for TNF-␣, GM-CSF, and G-CSF were 10 pg/ml, 2.5 pg/ml, and 7 pg/ml, respectively.
Monoclonal Abs (mAbs)
The mAb Leu 15 (immunoglobulin G1 (IgG1)), directed to human CR3, was purchased from Becton Dickinson (Franklin Lakes, NJ); the anti-FcRIII mAb 3G8 (IgG2a) was obtained from Medarex (Annandale, NJ). Isotypic non-binding controls of mouse IgG1 and IgG2a were purchased from Coulter (Hialeah, FL). Leu 15 blocks the iC3b binding site of CR3, and 3G8 blocks the Fc-binding site of FcRIII. Leu 15 and 3G8 were determined by flow cytometry to saturate surfaces of 10 6 PMNs at concentrations of 10 g/ml and 5 g/ml, respectively.
Purified IgG-Containing Type-Specific Ab
Purified IgG-containing type III GBS-specific Ab was prepared by ion exchange chromatography of sera from five healthy women vaccinated with a single dose of type III GBS polysaccharide-tetanus toxoid conjugate vaccine. 28 The concentration of III GBS-specific IgG by enzyme-linked immunosorbent assay was 102 g/ml.
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Opsonophagocytosis Assay
The PMN-mediated killing of opsonized III GBS was determined in a bactericidal assay referred to as an opsonophagocytosis assay. In all experiments, 10% serum containing Ͻ0.05 g/ml III GBS IgG Ab was used as a source of complement. Purified A-PMNs or N-PMNs (2 ϫ 10 6 PMNs/ml) were treated with TNF-␣, G-CSF, GM-CSF, or phosphate-buffered saline (PBS) for 5 minutes before the addition of 4 ϫ 10 6 CFU/ml III GBS. Samples taken before and after 60 minutes of incubation at 37°C with end-over-end mixing were diluted in saline and plated on trypticase soy agar containing 5% sheep erythrocytes (Becton Dickinson, Cockeysville, MD) for determination of CFU per milliliter. The bactericidal index (BI) was calculated as follows: 100 Ϫ ([CFU/ml t60 ]/[CFU/ml t0 ] ϫ 100). Positive controls for each experiment were tubes with serum containing III GBS-specific Ig Ab previously shown to result in a Ն95% BI in this assay. Negative controls were tubes without PMNs or PMNs treated with PBS buffer. Dose-response experiments were performed using 0.05 to 100 ng/ml of each cytokine. A concentration of 50 ng/ml of each cytokine was chosen for subsequent experiments to compare the effect on A-PMNs and N-PMNs.
Blocking Studies with mAb
The above assay was modified to study the role of CR3 and FcRIII receptors in the PMN-mediated killing of III GBS by GM-CSF-treated cells. PMNs were treated with GM-CSF or PBS (as described above) and subsequently incubated for 5 minutes at room temperature with saturating concentrations of the mAb (Leu 15 or 3G8) or isotypic controls (IgG1, IgG2a). Without washing the cells, III GBS (4 ϫ 10 6 CFU/ml) was added and the BI was determined.
Effect of Type-Specific Ab and GM-CSF on Killing of III GBS
To determine whether the killing of III GBS by GM-CSF-treated PMNs would be further enhanced by the presence of type III GBS IgG Ab, purified IgG was added to the reaction mixture. N-PMNs were pretreated with 10 ng/ml GM-CSF at a concentration comparable with the serum levels achieved when GM-CSF is administered to premature newborn infants. 30 Untreated N-PMNs were used as controls. Concentrations of IgG ranging from 0.125 to 4 g/ml were added. The BI was determined as described above.
Statistics
Data were analyzed by the Student unpaired t-test.
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RESULTS
To determine the optimal cytokine amount for these experiments, dose response studies were performed as summarized in Figure 1 , a-c. Treatment of A-PMNs with TNF-␣ increased the BI in a dosedependent manner. The increased BI was evident at a concentration as low as 0.5 ng/ml, and at 5 ng/ml, the BI was significantly greater than that for unstimulated controls ( p ϭ 0.04). Stimulation with increasing concentrations of G-CSF also produced a stepwise increase in the BI, but this did not reach statistical significance. With GM-CSF, the BI increased substantially with concentrations as low as 0.05 ng/ml, and at 100 ng/ml, the BI was significantly increased compared with controls ( p ϭ 0.05). At TNF-␣ or GM-CSF concentrations of 50 ng/ml, the BI with A-PMNs increased to 100% above baseline. Thus, this concentration was used in subsequent experiments.
The effect of these three cytokines on A-PMN-and N-PMN-mediated killing of III GBS then was assessed. As shown in the Table 1 , the BI increased significantly when A-PMNs were treated with TNF-␣ ( p Ͻ 0.01) or GM-CSF ( p Ͻ 0.01). When N-PMNs were used, priming with GM-CSF resulted in a significantly increased BI ( p Ͻ 0.01). Although N-PMNs treated with TNF-␣ and G-CSF produced increased killing of III GBS, this did not reach statistical significance.
For each of the five adult or cord blood samples tested, the endogenous serum concentrations of TNF-␣, G-CSF, and GM-CSF were lower than the levels required to achieve an enhanced bactericidal effect. The concentrations of TNF-␣ and GM-CSF in adult samples were less than the level of detection of the assay, and were between 9.4 and 41.1 pg/ml for G-CSF. In the cord blood samples, TNF-␣ was undetectable in four of five samples. In one, the level of TNF-␣ was 33.8 pg/ml. The concentration of G-CSF in cord blood was 38.9 to 87.6 pg/ml. GM-CSF was undetectable in each of the five cord blood samples.
Next, a possible mechanism by which GM-CSF treatment enhanced the PMN-mediated killing of III GBS was indirectly assessed by experiments in which CR3 or FcRIII receptors of GM-CSF-treated A-PMNs or N-PMNs were blocked with mAbs. PBS-treated PMNs were used as controls and had a BI of 41 Ϯ 25% for A-PMNs and 52 Ϯ 1% for N-PMNs. As shown in Figure 2 , the BI achieved with GM-CSFtreated A-PMNs declined from 72 Ϯ 16% to 62 Ϯ 16% ( p ϭ not significant) when CR3 receptors were blocked with Leu 15. Blockade of FcRIII receptors with 3G8 reduced the BI to control values ( p ϭ 0.03), as did the combination of Leu 15 and 3G8. Similar results were observed when N-PMNs were used. Blockade of CR3 with Leu 15 minimally reduced the killing by GM-CSF-treated N-PMNs from 73 Ϯ 7% to 63 Ϯ 7%. Blockade of FcRIII receptors of GM-CSF-treated N-PMNs significantly reduced the BI to 33 Ϯ 15% ( p ϭ 0.01). As noted with A-PMNs, the combination of both Leu 15 and 3G8 reduced the killing to a level similar to that for the control N-PMNs. Isotypic controls for these mAbs did not diminish killing (data not shown). G-CSF (b) , or GM-CSF (c) and PMN-mediated killing then was determined in an opsonophagocytic assay. A significant increase ( p ϭ 0.04) was noted for TNF-␣ at concentrations of 5 and 50 ng/ml and for GM-CSF at 100 ng/ml as indicated by the asterisk. Results are the mean Ϯ SD of three experiments. Because the preceding experiments used low III GBS-specific IgG Ab-containing sera (Ͻ0.05 g/ml), the potential effect of exogenous Ab was assessed. Physiologically achievable concentrations of GM-CSF (10 ng/ml) and III GBS-specific IgG Ab were used in these experiments. The addition of purified III GBS-specific IgG augmented, in a dose-dependent fashion, the opsonophagocytosis of III GBS by both GM-CSF-treated N-PMNs ( Figure 3 ) and untreated N-PMN controls (data not shown). This was observed at a concentration as low as 0.5 g/ml III GBS-specific IgG. With Ն1 g/ml III GBS-specific IgG in the reaction mixture, there was Ͼ1 log reduction in GBS and the increase in BI was statistically significant compared with control values (63 Ϯ 14%) ( p Յ 0.03).
DISCUSSION
These experiments indicate that incubation of human PMNs with exogenous TNF-␣ or GM-CSF increases the opsonophagocytosis of III GBS. Incubation of A-PMNs with TNF-␣ significantly increased the opsonophagocytosis of type III GBS. These results are in agreement with investigations that show that TNF-␣ increases the bactericidal activities of A-PMNs for other bacterial pathogens. [7] [8] [9] [10] [11] In contrast, incubation of N-PMNs with TNF-␣ only minimally increased opsonophagocytosis for type III GBS. Levels of TNF-␣ in sera from infants with sepsis range from 7 to 424 pg/ml and are lower than the level that was used in the current studies. 17 At sites of inflammation, where mononuclear cells and macrophages produce TNF-␣, the level may be higher and may induce increased bactericidal activity of PMNs locally. G-CSF-treated A-PMNs and N-PMNs had minimally increased killing of III GBS. Bober et al. 11 reported that G-CSF-treated PMNs and GM-CSF-treated PMNs were equivalent in their capacity to induce anti-bacterial phagocytosis of S. aureus but not C. albicans. This suggests that the efficacy of G-CSF for enhancing phagocytosis may vary depending on the microorganism. In our experiments, the priming effect was greatest for GM-CSF treatment of A-PMN and N-PMN. Our data corroborate the results of Fleischmann et al., 10 who reported enhanced phagocytosis of S. aureus by GM-CSF-treated A-PMNs, and those of Cairo et al., 19 who reported similar findings using N-PMNs.
GM-CSF increases the expression of receptors (CR1 and CR3) on PMNs; these receptors bind the complement components C3b and iC3b, which opsonize bacteria. 11, 22, 23 It has been shown that iC3b binds to the surface of opsonized III GBS, 32 and that blockade of the iC3b binding site of CR3 or CR1 modestly reduces the killing of III GBS by A-PMNs and N-PMNs. 24 GM-CSF also increases the expression of IgG (FcRIII) receptors. 22, 25 FcRIII mediates the attachment of IgG-coated particles to the PMN surface, interacts with CRs and FcRII receptors, and triggers exocytosis of PMN granules and cytoskeletal rearrangement. [33] [34] [35] FcRIII receptors have an accessory role for the uptake of opsonized III GBS by PMNs and, when blocked, the uptake of III GBS is reduced. 26 Our results extend these findings in that opsonophagocytosis of III GBS by GM-CSF-treated PMNs is significantly reduced by blockade of FcRIII receptors. One mechanism by which GM-CSF may enhance the opsonophagocytosis of III GBS is by increasing the expression of FcRIII receptors. Blockade of CR3 receptors only minimally reduced the killing of III GBS by GM-CSF-treated PMNs. We speculate that other CRs that are upregulated by GM-CSF, such as CR1, may have facilitated ingestion when CR3 was blocked. Furthermore, the previously demonstrated priming for oxidative metabolism that occurs with GM-CSF treatment may have contributed to the enhanced microbial killing observed. 19 Although the production of GM-CSF by neonatal mononuclear cells may be reduced, [12] [13] [14] it also has been shown that the bactericidal activity of N-PMNs can be increased by GM-CSF. 19 Deficiencies in neonatal host defenses contribute to susceptibility to GBS infections. The importance of PMNs and specific Ab in host defense against III GBS is well recognized. [1] [2] [3] Neutropenia is a clinical feature of GBS sepsis that has been associated with poor outcome. 36 Cairo et al. 37, 38 investigated the potential role of leukocyte transfusions to treat infants with neonatal sepsis. The use of CSFs as another means of correcting sepsis-associated neutropenia has been investigated. 20, 21, 30, 39, 40 The basal concentrations of GM-CSF in neonatal sera are negligible, and decreased GM-CSF expression and production may contribute to the development of neutropenia. 13, 14 In a recent clinical trial, administration of recombinant human GM-CSF to premature infants was well-tolerated, and peripheral blood PMN counts and CR3 receptor expression were significantly increased. 30 Although GM-CSF may increase N-PMN count and function, type III GBS is most efficiently killed by PMNs when opsonized with complement and capsular polysaccharide-specific Ab. 2 Givner 41 reported that commercially available human Ig preparations for intravenous use vary in pathogen-specific levels of Ab and in in vitro and in vivo functional activity, making the utility of these preparations for treating GBS infections questionable. However, human IgG preparations that are hyperimmune for type III GBS are protective in mouse and neonatal rat models of type III GBS infection and increase opsonophagocytosis of type III GBS in vitro. 42 Recently, IgG Ab produced in response to III GBS glycoconjugate vaccine given to healthy adults has been shown to be opsonic in vitro and protective in an experimental model. 28, 29 In our experiments, the in vitro effects of N-PMNs treated with GM-CSF promoted opsonophagocytosis of III GBS with a modest concentration of III GBS-specific IgG and complement. These findings are similar to those of Fleischmann et al., 10 who reported that GM-CSF-primed PMNs were more efficient when presented with S. aureus opsonized with Ab and complement than when presented with unopsonized organisms. The quantitative and qualitative effects of GM-CSF in enhancing phagocytic host defense and the importance of IgG-specific Ab as an opsonin suggest that each may be useful as an adjunct in improving host defense against III GBS. The present experiments have evaluated in vitro effects of GM-CSF-treated PMNs against III GBS. Further investigation of these agents in in vivo models is warranted.
